Pharmacogenetic Variability and Quality of Life in Adolescent Patients with Schizophrenia: The Impact of Metabolizer Status, Symptom Severity, and Adverse Reactions to Antipsychotic Treatment
: In adolescent schizophrenia, the CYP2D6-reduced metabolizer status is the strongest independent predictor of long-term QoL impairment, associated primarily through a substantially higher burden of treatment-related adverse effects (metabolic, endocrine, neurological, and sedative) rather than through persistence of psychotic symptoms alone. These findings support early pharmacogenetic testing to guide individualized dosing and improve tolerability and patient-reported outcomes.
Authors
- Adriana Cojocaru (ORCID: https://orcid.org/0000-0002-7362-3714)
- Liana Dehelean (ORCID: https://orcid.org/0000-0002-6326-1123)
- Delia Mira Berceanu Vaduva
- B.O. Bucatoș
- Laura Alexandra Nussbaum (ORCID: https://orcid.org/0000-0003-0422-918X)
- Nilima Rajpal Kundnani (ORCID: https://orcid.org/0000-0002-2824-7182)
- Abhinav Sharma (ORCID: https://orcid.org/0000-0002-0865-0054)
- A.M. Romoșan (ORCID: https://orcid.org/0000-0002-7669-2088)
- R. Romosan (ORCID: https://orcid.org/0000-0003-0621-896X)
Institutions
- Victor Babeș University of Medicine and Pharmacy Timișoara (RO)
Publication Details
- Journal
- Journal of Clinical Medicine
- Published
- 2026-04-11
- DOI
- https://doi.org/10.3390/jcm15082912
- Primary Topic
- Schizophrenia research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00